PrefMab PATIENT PREFERENCE TRIAL: STUDIED PREVIOUSLY UNTREATED DLBCL AND FL 1,2

PrefMab was a Phase IIIb randomized trial designed to evaluate patient preference with administration of RITUXAN HYCELA vs RITUXAN (rituximab), both in combination with chemotherapy

Patient Characteristics:

  • The percentage of male and female patients was similar
  • 51% of patients were 60 years of age or more
  • Median age was 60 years
  • 37% of patients had FL; 63% of patients had DLBCL

PATIENT EXPERIENCE RESULTS: AFTER CYCLE 8 1

Review the clinical development program